These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36796751)

  • 21. Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.
    Lane EL; Dunnett SB
    Behav Brain Res; 2010 Nov; 213(1):66-72. PubMed ID: 20434491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of l-dopa on attentional impairments in a rat model of Parkinson's disease.
    Smith ES; Hardy GA; Schallert T; Lee HJ
    Neuroscience; 2016 Nov; 337():295-305. PubMed ID: 27664460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
    Ko WK; Li Q; Bezard E
    Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Striatal ΔFosB gene suppression inhibits the development of abnormal involuntary movements induced by L-Dopa in rats.
    Beck G; Zhang J; Fong K; Mochizuki H; Mouradian MM; Papa SM
    Gene Ther; 2021 Dec; 28(12):760-770. PubMed ID: 33707771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.
    González-Aparicio R; Moratalla R
    Neurobiol Dis; 2014 Feb; 62():416-25. PubMed ID: 24140894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doxycycline and its derivative, COL-3, decrease dyskinesia induced by l-DOPA in hemiparkinsonian rats.
    Bortolanza M; do Nascimento GC; Raisman-Vozari R; Del-Bel E
    Br J Pharmacol; 2021 Jul; 178(13):2595-2616. PubMed ID: 33751546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
    Thomsen M; Stoica A; Christensen KV; Fryland T; Mikkelsen JD; Hansen JB
    Exp Neurol; 2022 Dec; 358():114209. PubMed ID: 35988699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats.
    Smith S; Sergio J; Coyle M; Elder K; Centner A; Cohen S; Terry M; Lipari N; Glinski J; Wheelis E; Budrow C; Bishop C
    Psychopharmacology (Berl); 2022 Jul; 239(7):2119-2132. PubMed ID: 35275226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arachidonyl-2'-chloroethylamide (ACEA), a synthetic agonist of cannabinoid receptor, increases CB
    Leija-Salazar M; Bermúdez de León M; González-Horta A; González-Hernández B
    Pharmacol Biochem Behav; 2020 Jul; 194():172950. PubMed ID: 32413434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats.
    Gil SJ; Park CH; Lee JE; Minn YK; Koh HC
    Brain Res Bull; 2011 Feb; 84(2):151-6. PubMed ID: 21163338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
    Iravani MM; Costa S; Jackson MJ; Tel BC; Cannizzaro C; Pearce RK; Jenner P
    Eur J Neurosci; 2001 Feb; 13(3):597-608. PubMed ID: 11168568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia.
    Bastide MF; Glangetas C; Doudnikoff E; Li Q; Bourdenx M; Fernagut PO; Dumont ÉC; Georges F; Bézard E
    Sci Rep; 2017 May; 7(1):2348. PubMed ID: 28539659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
    Lipari N; Centner A; Glinski J; Cohen S; Manfredsson FP; Bishop C
    Neurobiol Dis; 2023 Jan; 176():105965. PubMed ID: 36526089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acupuncture Alleviates Levodopa-Induced Dyskinesia via Melanin-Concentrating Hormone in Pitx3-Deficient aphakia and 6-Hydroxydopamine-Lesioned Mice.
    Kim YK; Lee AR; Park H; Yoo J; Ahn S; Jeon SH; Kim J; Park HJ
    Mol Neurobiol; 2019 Apr; 56(4):2408-2423. PubMed ID: 30030752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic Inflammation Increases the Susceptibility to Levodopa-Induced Dyskinesia in 6-OHDA Lesioned Rats by Targeting the NR2B-Medicated PKC/MEK/ERK Pathway.
    Yan A; Song L; Zhang Y; Wang X; Liu Z
    Front Aging Neurosci; 2020; 12():625166. PubMed ID: 33597857
    [No Abstract]   [Full Text] [Related]  

  • 38. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects.
    Albarrán-Bravo S; Ávalos-Fuentes JA; Cortés H; Rodriguez-Sánchez M; Leyva-García N; Rangel-Barajas C; Erlij D; Florán B
    Biomolecules; 2019 Sep; 9(9):. PubMed ID: 31480516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
    Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
    Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.